meningococcal group a, c, w-135 and y conjugate vaccine (Chiron Corporation)

Chiron MenACWY is a quadrivalent meningococcal conjugate vaccine developed by Chiron Corporation (later acquired by Novartis and then GSK) to prevent invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, W-135, and Y. The vaccine consists of capsular polysaccharides from these four serogroups, each individually conjugated to a non-toxic mutant of diphtheria toxin known as CRM197. This conjugation converts the T-cell-independent polysaccharide antigens into T-cell-dependent antigens, thereby inducing a more robust immune response and immunological memory, particularly in infants and adolescents. The vaccine was extensively studied in Phase 3 trials, including evaluations of its safety and immunogenicity when administered concomitantly with other adolescent vaccines such as Tdap (Boostrix). It is currently marketed under the brand name Menveo.

Brand names

Menveo

Other names

MenACWY-CRM197MenACWY-CRM-197MenACWY-CRM 197Quadrivalent meningococcal conjugate vaccine